Baidu
map

Int J Epidemiol:肌萎缩侧索硬化症全球发病率研究(荟萃分析)

2016-05-23 Seven L MedSci原创

研究者对现有文献数据等进行了一项系统回顾和荟萃分析,以评估肌萎缩侧索硬化症(ALS)的全球发生率变化。研究者检索了MEDLINE、EMBASE等数据库,纳入了基于人群的研究中诊断为ALS的患者。计算了ALS的粗发生率和标准化发生率(使用2010年美国人群,年龄、性别的标准化)。荟萃分析中使用看随机效应模型和meta回归,并调查了研究人口特征、研究方法的异质性。最终选定了44篇研究,覆盖11个次大陆

研究者对现有文献数据等进行了一项系统回顾和荟萃分析,以评估肌萎缩侧索硬化症(ALS)的全球发生率变化。

研究者检索了MEDLINE、EMBASE等数据库,纳入了基于人群的研究中诊断为ALS的患者。计算了ALS的粗发生率和标准化发生率(使用2010年美国人群,年龄、性别的标准化)。荟萃分析中使用看随机效应模型和meta回归,并调查了研究人口特征、研究方法的异质性。

最终选定了44篇研究,覆盖11个次大陆的45地理区域。共有13146例ALS,随访了8亿2500万人年(PYFU)。合并后分析,全球ALS的粗发生率为1.75 (1.55-1.96)/100 000 PYFU,标准化发病率为1.68 (1.50-1.85)/100 000 PYFU。ALS标准化发病率在以下具有异质性:北欧[1.89 (1.46-2.32)/100 000 PYFU] 、东亚 [0.83 (0.42-1.24)/100 000 PYFU, 中国和日本,P = 0.001]、南亚 [0.73 (0.58-0.89)/100 000/PYFU,伊朗, P = 0.02]。相反,欧洲、北美和新西兰的ALS发病率差不多(合并后ALS标准化发病率为1.81 (1.66-1.97)/100 000 PYFU)。

研究结果表明,ALS的发病率在全球不同区域存在差异,以后还需要国际联盟一起调查祖先、环境和ALS发病率间的联系。

原始出处:

Marin B, Boumédiene F,et al.Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis.Int J Epidemiol. 2016 May 16. pii: dyw061. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1681305, encodeId=022f1681305d7, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Sun Jan 29 07:18:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823276, encodeId=d80b18232e694, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Jul 18 04:18:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836882, encodeId=7589183688200, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Mar 26 15:18:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982917, encodeId=64a3198291e4f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Aug 12 01:18:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695775, encodeId=0e521695e75fb, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 13 11:18:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503064, encodeId=8b46150306476, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523439, encodeId=4ea815234391c, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=)]
    2017-01-29 venlin
  2. [GetPortalCommentsPageByObjectIdResponse(id=1681305, encodeId=022f1681305d7, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Sun Jan 29 07:18:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823276, encodeId=d80b18232e694, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Jul 18 04:18:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836882, encodeId=7589183688200, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Mar 26 15:18:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982917, encodeId=64a3198291e4f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Aug 12 01:18:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695775, encodeId=0e521695e75fb, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 13 11:18:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503064, encodeId=8b46150306476, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523439, encodeId=4ea815234391c, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1681305, encodeId=022f1681305d7, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Sun Jan 29 07:18:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823276, encodeId=d80b18232e694, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Jul 18 04:18:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836882, encodeId=7589183688200, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Mar 26 15:18:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982917, encodeId=64a3198291e4f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Aug 12 01:18:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695775, encodeId=0e521695e75fb, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 13 11:18:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503064, encodeId=8b46150306476, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523439, encodeId=4ea815234391c, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1681305, encodeId=022f1681305d7, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Sun Jan 29 07:18:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823276, encodeId=d80b18232e694, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Jul 18 04:18:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836882, encodeId=7589183688200, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Mar 26 15:18:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982917, encodeId=64a3198291e4f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Aug 12 01:18:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695775, encodeId=0e521695e75fb, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 13 11:18:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503064, encodeId=8b46150306476, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523439, encodeId=4ea815234391c, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1681305, encodeId=022f1681305d7, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Sun Jan 29 07:18:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823276, encodeId=d80b18232e694, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Jul 18 04:18:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836882, encodeId=7589183688200, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Mar 26 15:18:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982917, encodeId=64a3198291e4f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Aug 12 01:18:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695775, encodeId=0e521695e75fb, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 13 11:18:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503064, encodeId=8b46150306476, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523439, encodeId=4ea815234391c, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=)]
    2016-12-13 chendoc252
  6. [GetPortalCommentsPageByObjectIdResponse(id=1681305, encodeId=022f1681305d7, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Sun Jan 29 07:18:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823276, encodeId=d80b18232e694, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Jul 18 04:18:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836882, encodeId=7589183688200, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Mar 26 15:18:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982917, encodeId=64a3198291e4f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Aug 12 01:18:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695775, encodeId=0e521695e75fb, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 13 11:18:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503064, encodeId=8b46150306476, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523439, encodeId=4ea815234391c, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1681305, encodeId=022f1681305d7, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Sun Jan 29 07:18:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1823276, encodeId=d80b18232e694, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Mon Jul 18 04:18:00 CST 2016, time=2016-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1836882, encodeId=7589183688200, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Sun Mar 26 15:18:00 CST 2017, time=2017-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982917, encodeId=64a3198291e4f, content=<a href='/topic/show?id=a7a7e359478' target=_blank style='color:#2F92EE;'>#硬化症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73594, encryptionId=a7a7e359478, topicName=硬化症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Fri Aug 12 01:18:00 CST 2016, time=2016-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695775, encodeId=0e521695e75fb, content=<a href='/topic/show?id=03b98809697' target=_blank style='color:#2F92EE;'>#萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88096, encryptionId=03b98809697, topicName=萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=53fc29868494, createdName=chendoc252, createdTime=Tue Dec 13 11:18:00 CST 2016, time=2016-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503064, encodeId=8b46150306476, content=<a href='/topic/show?id=a71481058ca' target=_blank style='color:#2F92EE;'>#肌萎缩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81058, encryptionId=a71481058ca, topicName=肌萎缩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eebd9606217, createdName=neizongke, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523439, encodeId=4ea815234391c, content=<a href='/topic/show?id=e7f5810596c' target=_blank style='color:#2F92EE;'>#肌萎缩侧索硬化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81059, encryptionId=e7f5810596c, topicName=肌萎缩侧索硬化)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3c4711523273, createdName=liuyong2984, createdTime=Wed May 25 13:18:00 CST 2016, time=2016-05-25, status=1, ipAttribution=)]

相关资讯

JAMA Neurol:ACEI可降肌萎缩侧索硬化症风险?

台湾一项研究表明,血管紧张素转化酶抑制剂(ACEI)应用与肌萎缩侧索硬化症(ALS)形成风险存在剂量依赖负相关性。论文于11月10在线发表于《美国医学会杂志·神经病学》。此项基于人群的病例对照研究共纳入729例新诊断ALS患者,以及14580例性别、年龄、居住地和保险与之相匹配的对照者。以累积限定日剂量(cDDD)代表药物应用持续时间评估ACEI应用与ALS形成风险之间的相关性。结果显示,

Science:科学家发现ALS和FTD等神经退行性疾病病因

来自美国梅奥诊所(Mayo Clinic)的科学家们构建出了一种新型小鼠,其显示出与肌萎缩侧索硬化症(ALS,又称渐冻人症)和额颞痴呆(FTD)最常见的遗传形式相关的一些症状和神经退行性变。ALS和FTD这两种疾病都是由于C9ORF72基因突变引起。这项研究发布在近期的《科学》(Science)杂志上。  美国有3万多ALS患者,ALS破坏了控制包括说话、行走、呼吸和吞咽等基本动作的神

Lancet:胃造瘘术对肌萎缩侧索硬化症的安全性和临床疗效

    背景  胃造瘘术灌食通常用来支持肌萎缩侧索硬化症患者谁开发严重吞咽困难的现象。虽然由美国神经病学学会和欧洲神经病学学会联合会推荐,目前没有证据表明胃造口插入的最佳时机与方法。该研究的目的是比较胃造口插入方法的安全性和临床疗效。    方法  在这个大的,纵向的,前瞻性队列研究(ProGas)中,纳入的患者是有明确的,可能的,实验室

Scientific Reports:日发现一种蛋白质或能推迟渐冻症发展

日本岐阜药科大学教授原英彰率领的研究小组在8月13日的英国《科学报告》(Scientific Reports)杂志网络版上报告说,他们发现了一种能推迟渐冻症发展的蛋白质。这一发现有望为弄清该病的发病机制和开发新的治疗药物作出贡献。 肌萎缩侧索硬化症俗称渐冻症,这种疾病的患者运动神经出现障碍,导致全身肌肉逐渐变得无力。渐冻症患者约有10%属于遗传性患病。由于不清楚详细的致病原因,医学界一直未找到根

Baidu
map
Baidu
map
Baidu
map